Publications
184
Citations
11,903
Est. group size
~4
Recurring co-author estimate
Active years
42
Publishing since 1985
Typically publishes in teams of ~17 · 7% small-team papers (≤3 authors) · across 13 venues
- Associations between self-efficacy and symptom burden in young women with breast cancer initiating endocrine therapy (ET) on SWOG S2010.
Journal of Clinical Oncology · 2026
- Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007)
JNCI Journal of the National Cancer Institute · 2026
- Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women
JAMA Oncology · 2025
- Updated efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patients with <i>PIK3CA</i> -mutant HR+HER2- advanced breast cancer: ReDiscover trial.
Journal of Clinical Oncology · 2025
- Abstract PS7-01: Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
Clinical Cancer Research · 2025
- Practice patterns related to ovarian function suppression in the SWOG S2010 clinical trial of young women with breast cancer.
Journal of Clinical Oncology · 2025
- Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial
UNC Libraries · 2025
- Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
JNCI Journal of the National Cancer Institute · 2024
- Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
Journal of Clinical Oncology · 2024
- Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer
Cancer Research · 2024
- First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
Journal of Clinical Oncology · 2024
- Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort
Cancer Research · 2024
- Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.
Journal of Clinical Oncology · 2024
- 390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial
Annals of Oncology · 2023
- 205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
ESMO Open · 2023
- Journal of Clinical Oncology×17
- Cancer Research×14
- Breast Cancer Research and Treatment×6
- Clinical Cancer Research×5
- JAMA Oncology×3
- Sagar Sardesai
Medicine · The Ohio State University
- Erin F. Cobain
Medicine · University of Michigan
- Preeti Sudheendra
Medicine · The Ohio State University
- Jiayu Wang
Medicine · University of Michigan
- Oana C. Danciu
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile